-
Enduring Clinical Remission in Refractory Celiac Disease Type II with Tofacitinib: An Open-Label Clinical Study
Dieckman, T., Schumann, M., Beaumont, H., Bontkes, H. J., Koning, F., Bouma, G., Byrnes, V., McCarthy, J., Neefjes-Borst, A., Loddenkemper, C., van Bergen, J., Weegh, M. O. D. & RCDII Tofacitinib Consortium, 2024, (E-pub ahead of print) In: Clinical Gastroenterology and Hepatology.Research output: Contribution to journal › Short survey › Academic › peer-review
-
Celiac disease: New therapies on the horizon
Dieckman, T., Koning, F. & Bouma, G., 1 Oct 2022, In: Current Opinion in Pharmacology. 66, 102268.Research output: Contribution to journal › Review article › Academic › peer-review
-
Single-Cell Analysis of Refractory Celiac Disease Demonstrates Inter- and Intra-Patient Aberrant Cell Heterogeneity
Dieckman, T., Schreurs, M., Mahfouz, A., Kooy-Winkelaar, Y., Neefjes-Borst, A., Bouma, G. & Koning, F., 1 Jan 2022, In: Cellular and Molecular Gastroenterology and Hepatology. 14, 1, p. 173-192 20 p.Research output: Contribution to journal › Article › Academic › peer-review
- All publications
